vs
安进（AMGN）与COMMUNITY HEALTH SYSTEMS INC（CYH）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是COMMUNITY HEALTH SYSTEMS INC的3.2倍（$9.9B vs $3.1B）。安进净利率更高（13.5% vs 3.5%，领先10.0%）。安进同比增速更快（8.6% vs -4.8%）。安进自由现金流更多（$961.0M vs $172.0M）。过去两年安进的营收复合增速更高（15.1% vs -0.5%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
社区卫生系统公司总部位于美国田纳西州富兰克林，是财富500强企业。按急症护理机构数量计算，该公司曾是美国最大的综合医院医疗服务提供商。2014年它旗下有约200家医院，到2021年机构数量缩减至约85家。
AMGN vs CYH — 直观对比
营收规模更大
AMGN
是对方的3.2倍
$3.1B
营收增速更快
AMGN
高出13.4%
-4.8%
净利率更高
AMGN
高出10.0%
3.5%
自由现金流更多
AMGN
多$789.0M
$172.0M
两年增速更快
AMGN
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $3.1B |
| 净利润 | $1.3B | $110.0M |
| 毛利率 | 69.8% | 85.6% |
| 营业利润率 | 27.6% | 14.5% |
| 净利率 | 13.5% | 3.5% |
| 营收同比 | 8.6% | -4.8% |
| 净利润同比 | 112.6% | 254.9% |
| 每股收益（稀释后） | $2.45 | $0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNCYH
| Q4 25 | $9.9B | $3.1B | ||
| Q3 25 | $9.6B | $3.1B | ||
| Q2 25 | $9.2B | $3.1B | ||
| Q1 25 | $8.1B | $3.2B | ||
| Q4 24 | $9.1B | $3.3B | ||
| Q3 24 | $8.5B | $3.1B | ||
| Q2 24 | $8.4B | $3.1B | ||
| Q1 24 | $7.4B | $3.1B |
净利润AMGNCYH
| Q4 25 | $1.3B | $110.0M | ||
| Q3 25 | $3.2B | $130.0M | ||
| Q2 25 | $1.4B | $282.0M | ||
| Q1 25 | $1.7B | $-13.0M | ||
| Q4 24 | $627.0M | $-71.0M | ||
| Q3 24 | $2.8B | $-391.0M | ||
| Q2 24 | $746.0M | $-13.0M | ||
| Q1 24 | $-113.0M | $-41.0M |
毛利率AMGNCYH
| Q4 25 | 69.8% | 85.6% | ||
| Q3 25 | 67.8% | 85.1% | ||
| Q2 25 | 67.2% | 85.0% | ||
| Q1 25 | 63.6% | 84.5% | ||
| Q4 24 | 65.7% | 84.5% | ||
| Q3 24 | 61.1% | 84.8% | ||
| Q2 24 | 61.4% | 84.6% | ||
| Q1 24 | 57.0% | 84.5% |
营业利润率AMGNCYH
| Q4 25 | 27.6% | 14.5% | ||
| Q3 25 | 26.4% | 7.9% | ||
| Q2 25 | 28.9% | 16.3% | ||
| Q1 25 | 14.5% | 9.0% | ||
| Q4 24 | 25.4% | 8.5% | ||
| Q3 24 | 24.1% | -6.6% | ||
| Q2 24 | 22.8% | 7.6% | ||
| Q1 24 | 13.3% | 7.4% |
净利率AMGNCYH
| Q4 25 | 13.5% | 3.5% | ||
| Q3 25 | 33.7% | 4.2% | ||
| Q2 25 | 15.6% | 9.0% | ||
| Q1 25 | 21.2% | -0.4% | ||
| Q4 24 | 6.9% | -2.2% | ||
| Q3 24 | 33.3% | -12.7% | ||
| Q2 24 | 8.9% | -0.4% | ||
| Q1 24 | -1.5% | -1.3% |
每股收益（稀释后）AMGNCYH
| Q4 25 | $2.45 | $0.82 | ||
| Q3 25 | $5.93 | $0.96 | ||
| Q2 25 | $2.65 | $2.09 | ||
| Q1 25 | $3.20 | $-0.10 | ||
| Q4 24 | $1.17 | $-0.53 | ||
| Q3 24 | $5.22 | $-2.95 | ||
| Q2 24 | $1.38 | $-0.10 | ||
| Q1 24 | $-0.21 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $260.0M |
| 总债务越低越好 | $54.6B | $10.4B |
| 股东权益账面价值 | $8.7B | $-1.4B |
| 总资产 | $90.6B | $13.2B |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNCYH
| Q4 25 | $9.1B | $260.0M | ||
| Q3 25 | $9.4B | $123.0M | ||
| Q2 25 | $8.0B | $456.0M | ||
| Q1 25 | $8.8B | $431.0M | ||
| Q4 24 | $12.0B | $37.0M | ||
| Q3 24 | $9.0B | $33.0M | ||
| Q2 24 | $9.3B | $39.0M | ||
| Q1 24 | $9.7B | $48.0M |
总债务AMGNCYH
| Q4 25 | $54.6B | $10.4B | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | $11.5B | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNCYH
| Q4 25 | $8.7B | $-1.4B | ||
| Q3 25 | $9.6B | $-1.5B | ||
| Q2 25 | $7.4B | $-1.6B | ||
| Q1 25 | $6.2B | $-1.9B | ||
| Q4 24 | $5.9B | $-1.9B | ||
| Q3 24 | $7.5B | $-1.8B | ||
| Q2 24 | $5.9B | $-1.4B | ||
| Q1 24 | $5.0B | $-1.4B |
总资产AMGNCYH
| Q4 25 | $90.6B | $13.2B | ||
| Q3 25 | $90.1B | $13.2B | ||
| Q2 25 | $87.9B | $13.6B | ||
| Q1 25 | $89.4B | $13.9B | ||
| Q4 24 | $91.8B | $14.1B | ||
| Q3 24 | $90.9B | $13.9B | ||
| Q2 24 | $90.9B | $14.4B | ||
| Q1 24 | $93.0B | $14.4B |
负债/权益比AMGNCYH
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $266.0M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $172.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 5.5% |
| 资本支出强度资本支出/营收 | 6.5% | 3.0% |
| 现金转化率经营现金流/净利润 | 1.20× | 2.42× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $208.0M |
8季度趋势，按日历期对齐
经营现金流AMGNCYH
| Q4 25 | $1.6B | $266.0M | ||
| Q3 25 | $4.7B | $69.0M | ||
| Q2 25 | $2.3B | $88.0M | ||
| Q1 25 | $1.4B | $120.0M | ||
| Q4 24 | $4.8B | $216.0M | ||
| Q3 24 | $3.6B | $67.0M | ||
| Q2 24 | $2.5B | $101.0M | ||
| Q1 24 | $689.0M | $96.0M |
自由现金流AMGNCYH
| Q4 25 | $961.0M | $172.0M | ||
| Q3 25 | $4.2B | $4.0M | ||
| Q2 25 | $1.9B | $-3.0M | ||
| Q1 25 | $980.0M | $35.0M | ||
| Q4 24 | $4.4B | $107.0M | ||
| Q3 24 | $3.3B | $-3.0M | ||
| Q2 24 | $2.2B | $13.0M | ||
| Q1 24 | $459.0M | $3.0M |
自由现金流率AMGNCYH
| Q4 25 | 9.7% | 5.5% | ||
| Q3 25 | 44.4% | 0.1% | ||
| Q2 25 | 20.8% | -0.1% | ||
| Q1 25 | 12.0% | 1.1% | ||
| Q4 24 | 48.4% | 3.3% | ||
| Q3 24 | 39.0% | -0.1% | ||
| Q2 24 | 26.5% | 0.4% | ||
| Q1 24 | 6.2% | 0.1% |
资本支出强度AMGNCYH
| Q4 25 | 6.5% | 3.0% | ||
| Q3 25 | 4.6% | 2.1% | ||
| Q2 25 | 4.0% | 2.9% | ||
| Q1 25 | 5.0% | 2.7% | ||
| Q4 24 | 4.1% | 3.3% | ||
| Q3 24 | 3.0% | 2.3% | ||
| Q2 24 | 2.8% | 2.8% | ||
| Q1 24 | 3.1% | 3.0% |
现金转化率AMGNCYH
| Q4 25 | 1.20× | 2.42× | ||
| Q3 25 | 1.46× | 0.53× | ||
| Q2 25 | 1.59× | 0.31× | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
CYH
| Managed Care And Other Third Party Payors | $1.5B | 49% |
| Medicare Managed Care | $570.0M | 18% |
| Medicare | $512.0M | 16% |
| Medicaid | $464.0M | 15% |
| Self Pay Revenue | $34.0M | 1% |
